Device Trial Radar · NCT06135727
Screening Protocol
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
26
Actual
Start
Nov 7, 2023
Primary completion
Aug 2, 2024
Study completion Aug 2, 2024
Sponsor
- Lead sponsor
- Topcon CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to collect data for the development and validation a screening process using aggregate data. In this study, data collection will encompass both retrospective and prospective approaches across multiple sites in the United States.
Conditions
- Glaucoma
Interventions
Maestro2 OCTDevice
3D Wide (12mmx9mm) OCT scan using the Maestro (Topcon, Japan)
Primary outcomes
What the sponsor says the trial is designed to measure.
- RNFL and GCL thicknessTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Topcon
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.